多线治疗后进展性mCRPC中177Lu-PSMA-617 PRLT的疗效、预后变量与临床结局:双示踪剂PET-CT高FDG摄取与Gleason评分的预后意义
回顾性分析40例多线治疗后进展性mCRPC患者接受177Lu-PSMA-617 PRLT的疗效与预后因素。中位OS 12个月、中位PFS 7个月,87.5%患者FDG摄取阳性;高FDG摄取与侵袭性生物学及Gleason评分升高相关,PSA-DT阴性者1年PFS更优(52.5% vs 47.5%,p=0.029)。治疗耐受性好,毒性低。
要点
- 高FDG摄取(87.5%患者)与侵袭性生物学、Gleason评分升高及更差12个月PFS相关。
- 治疗后PSA-DT阴性者1年PFS优于阳性者(52.5% vs 47.5%,p=0.029)。
- 68Ga-PSMA-11高摄取的转移性淋巴结病灶对177Lu-PSMA-617 PRLT反应优于肝和骨骼病灶。
核心结论
- 177Lu-PSMA-617 PRLT在多线治疗后进展性mCRPC中耐受性好,可产生疾病控制并获良好症状和生化反应,毒性低;高FDG摄取与侵袭性生物学、Gleason评分升高及更差12个月PFS相关;治疗后PSA-DT阴性者PFS更长。
研究设计与样本
- 回顾性研究(原文称retroprospective),纳入2017年3月至2019年2月在本院接受177Lu-PSMA-617 PRLT且≥2周期的mCRPC患者40例(年龄46–84岁,中位63岁),评估68Ga-PSMA-11 PET-CT、18FDG PET-CT、PSA变化、HRQoL量表(ECOG/Karnofsky)及Gleason评分与结局的关系。
关键影像表现/征象
- FDG摄取见于87.5%(n=35)患者;68Ga-PSMA-11高摄取的转移性淋巴结病灶对177Lu-PSMA-617 PRLT反应优于肝和骨骼病灶。
诊断标准与关键数值
- 疗效评估分三类:症状、生化、影像反应;症状和生化尺度上21例为反应者(CR、PR、SD)、19例为非反应者(PD),分子影像反应上16例(43%)为反应者、21例(57%)为非反应者;中位OS 12个月、中位PFS 7个月;PSA-DT阴性者1年PFS 52.5% vs 阳性者47.5%(p=0.029);接受>2周期者较2周期者PSA-DT阴性率更高(p=0.03)。
临床应用与阅片要点
- 对多线治疗后进展性mCRPC患者,177Lu-PSMA-617 PRLT可考虑用于疾病控制;阅片时需评估FDG摄取(高摄取提示侵袭性生物学和更差PFS)及PSA-DT(阴性提示更长PFS),并注意淋巴结病灶反应优于肝和骨骼病灶。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the therapeutic response, progression free survival (PFS), overall survival (OS) and clinical toxicity of 177Lu-PSMA-617 PSMA targeted radioligand therapy (PRLT) in the setting of heavily pre-treated metastatic castrate-resistant prostate cancer (mCPRC) patients and also examine the association of prognostic variables with therapeutic outcome in such patient cohort.
METHODS: We examined the medical records of mCRPC patients who had undergone 177Lu-PSMA-617 PRLT from March 2017 to February 2019 in our institute. Patients receiving equal to or more than two cycles were included and analyzed in this retroprospective study.The 68Ga-PSMA-11 PET-CT and 18-fludeoxyglucose positron emission tomography (18FDG PET)-CT scan findings, serum prostate-specific antigen (PSA) change, health-related quality of life (HRQoL) scales (Eastern Cooperative Oncology Group/Karnofsky score) and Gleason score were assessed for their implications on the outcome of therapy. The treatment response was evaluated under three categories: (a) symptomatic (b) biochemical and (c) imaging response.The PFS and OS following first PRLT were determined and the association of various variables with PSA doubling time (DT) and FDG uptake in the lesions were analyzed. Toxicity assessment was undertaken objectively by National Cancer Institute-Common Terminology Criteria for Adverse Events scale v. 5.0 for haematological and nephrotoxicity, and salivary gland toxicity assessed by xerostomia inventory score.
RESULTS: A total of 40 mCRPC patients (age range: 46-84 years; median 63 years), who had undergone 177Lu-PSMA-617 PRLT, of at least two cycles was identified and selected for the analysis. FDG uptake was noted in 87.5% of patients (n = 35). Out of 40 cases, 21 were responders (CR, PR and SD) and 19 were non-responders (PD) on symptomatic and biochemical scales while on molecular imaging response, 16 (43%) were responders and remaining 21 (57%) were non-responders. Lesion-wise, 68Ga-PSMA-11 avid metastatic nodal disease responded well with 177Lu PSMA-617 PRLT, as compared to hepatic and skeletal lesions. The median OS and PFS was 12 and 7 months respectively following first PRLT. Patients with negative serum PSA-DT demonstrated superior 1 year PFS as compared to those with positive serum PSA-DT (52.5 vs 47.5%) (p = 0.029). Patients receiving greater than two cycles PRLT demonstrated a higher negative PSA-DT as compared to those receiving two cycles (p-value = 0.03). Grade 1 xerostomia was observed in two patients (5%) (mean xerostomia score of 23), haematotoxicity in seven patients [Grade I (n = 2, 5%) and Grade II (n = 5, 14%)].
CONCLUSION: 177Lu-PSMA-617 PRLT was well-tolerated and able to produce disease control with good symptomatic and biochemical responses in the context of heavily pre-treated mCRPC with progressive disease, with low toxicity profile. Evident association of high FDG uptake was observed with aggressive disease biology coupled with increasing Gleason score and poorer 12 months PFS. Negative PSA-DT following therapy demonstrated longer PFS. The results demonstrate important future role of 177Lu-PSMA-617 PRLT in the treatment of mCRPC.
ADVANCES IN KNOWLEDGE: The present work explored in a large teriary cancer care setting, the efficacy of 177Lu-PSMA-617 PRLT, in an aggressive and unselected subset of mCRPC. The response and outcome was correlated with a number of prognostic variables, including molecular imaging findings (FDG uptake in the metastatic lesions), PSA DT and Gleason score.
引用
- Suman S, Parghane RV, Joshi A, et al. Therapeutic efficacy, prognostic variables and clinical outcome of 177Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohort. Br J Radiol. 2019. PMID: 31600089. doi:10.1259/bjr.20190380
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。